Skip to main content
Erschienen in:

01.03.2010 | Leitthema

Konventionelle Behandlung von Patienten mit multiplem Myelom

verfasst von: Prof. Dr. H. Ludwig, N. Zojer

Erschienen in: Die Onkologie | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Für ältere Patienten sowie für jene jüngeren Patienten mit multiplem Myelom, für die eine autologe Transplantation nicht in Frage kommt, stellt die konventionelle Behandlung die Therapie der Wahl dar. In den letzten Jahren konnten durch die Einführung der neuen Substanzen Thalidomid, Bortezomib und Lenalidomid das therapeutische Spektrum wesentlich erweitert und damit die Therapieergebnisse deutlich verbessert werden. Die Therapiewahl beim individuellen Patienten sollte aufgrund von patienten- und tumorspezifischer Faktoren wie z. B. zytogenetischer Risikofaktoren erfolgen. Für die Erstlinientherapie stehen mehrere in Phase-III-Studien etablierte IMiD- und Bortezomib-basierte Therapieprotokolle zur Verfügung, mit denen Ansprechraten von 60–85%, ein medianes progressionsfreies Überleben von 17–25 Monaten und eine Verlängerung der Gesamtüberlebenszeit erreicht werden können.
Literatur
1.
Zurück zum Zitat Mateos MV, Lopez-Corral L, Hernandez MT et al (2009) Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (Len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: Results of the first interim analysis. Presented at: 2009 meeting of the American Society of Hematology, New Orleans, Abstract # 614, Blood 114:254 Mateos MV, Lopez-Corral L, Hernandez MT et al (2009) Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (Len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: Results of the first interim analysis. Presented at: 2009 meeting of the American Society of Hematology, New Orleans, Abstract # 614, Blood 114:254
2.
Zurück zum Zitat Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 370:1209–1218CrossRefPubMed Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 370:1209–1218CrossRefPubMed
3.
Zurück zum Zitat Hulin C, Facon T, Rodon P et al (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 Trial. J Clin Oncol 27:3664–3670CrossRefPubMed Hulin C, Facon T, Rodon P et al (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 Trial. J Clin Oncol 27:3664–3670CrossRefPubMed
4.
Zurück zum Zitat Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 367:825–831CrossRefPubMed Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 367:825–831CrossRefPubMed
5.
Zurück zum Zitat Palumbo A, Bringhen S, Liberati AM et al (2008) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood 112:3107–3114CrossRefPubMed Palumbo A, Bringhen S, Liberati AM et al (2008) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood 112:3107–3114CrossRefPubMed
6.
Zurück zum Zitat Gulbrandsen N, Waage A, Gimsing P et al (2008) A randomised placebo controlled study with melphalan/prednisone versus melphalan/prednisone/thalidomide: quality of life and toxicity. Haematologica 93(Suppl 1):Abstract #209 Gulbrandsen N, Waage A, Gimsing P et al (2008) A randomised placebo controlled study with melphalan/prednisone versus melphalan/prednisone/thalidomide: quality of life and toxicity. Haematologica 93(Suppl 1):Abstract #209
7.
Zurück zum Zitat Wijermans PW, Zweegman S, Marwijk Kooy M van et al (2009) MP versus MPT in elderly myeloma patients: the final outcome of the HOVON-49 study. Clin Lymphoma Myeloma 9(Suppl 1):Abstract #116 Wijermans PW, Zweegman S, Marwijk Kooy M van et al (2009) MP versus MPT in elderly myeloma patients: the final outcome of the HOVON-49 study. Clin Lymphoma Myeloma 9(Suppl 1):Abstract #116
8.
Zurück zum Zitat Kapoor S, Rajkumar SV, Dispensieri A et al (2009) Melphalan and Prednisone (mp) versus Melphalan, Prednisone and Thalidomide (MPT) as initial therapy for previously untreated elderly and/or transplant ineligible patients with multiple myeloma: A meta-analysis of randomized controlled trials. presented at: 2009 meeting of the American Society of Hematology, New Orleans, Abstract # 615, Blood 114:252 Kapoor S, Rajkumar SV, Dispensieri A et al (2009) Melphalan and Prednisone (mp) versus Melphalan, Prednisone and Thalidomide (MPT) as initial therapy for previously untreated elderly and/or transplant ineligible patients with multiple myeloma: A meta-analysis of randomized controlled trials. presented at: 2009 meeting of the American Society of Hematology, New Orleans, Abstract # 615, Blood 114:252
9.
Zurück zum Zitat Morgan GJ, Davies FE, Owen RG et al (2007) Thalidomide combinations improve response rates; Results from the MRC IX study. Presented at: 2007 meeting of the American Society of Hematology. Blood 110:Abstract #3593 Morgan GJ, Davies FE, Owen RG et al (2007) Thalidomide combinations improve response rates; Results from the MRC IX study. Presented at: 2007 meeting of the American Society of Hematology. Blood 110:Abstract #3593
10.
Zurück zum Zitat Owen RG, Morgan GJ, Jackson H et al (2009) MRC Myeloma IX: Preliminary results from the non-intensive study. Clin Lymphoma Myeloma 9(Suppl 1):Abstract #547 Owen RG, Morgan GJ, Jackson H et al (2009) MRC Myeloma IX: Preliminary results from the non-intensive study. Clin Lymphoma Myeloma 9(Suppl 1):Abstract #547
11.
Zurück zum Zitat Ludwig H, Hajek R, Tothova E et al (2009) Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113:3435–3442CrossRefPubMed Ludwig H, Hajek R, Tothova E et al (2009) Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113:3435–3442CrossRefPubMed
12.
Zurück zum Zitat San Miguel J, Schlag R, Khuageva N et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917CrossRef San Miguel J, Schlag R, Khuageva N et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917CrossRef
13.
Zurück zum Zitat San Miguel J, Schlag R, Khuageva N et al (2008) Updated follow-up and results of subsequent therapy in the phase III VISTA trial: Bortezomib plus melphalan–prednisone versus melphalan–prednisone in newly diagnosed multiple myeloma. presented at: 2008 meeting of the American Society of Hematology in San Francisco. Blood 112:Abstract #650 San Miguel J, Schlag R, Khuageva N et al (2008) Updated follow-up and results of subsequent therapy in the phase III VISTA trial: Bortezomib plus melphalan–prednisone versus melphalan–prednisone in newly diagnosed multiple myeloma. presented at: 2008 meeting of the American Society of Hematology in San Francisco. Blood 112:Abstract #650
14.
Zurück zum Zitat Dhawan R, Meunier J, Regnault R et al (2009) Impact of complete response on health-related quality of life in newly diagnosed multiple myeloma patients: results from the VISTA trial. Clin Lymphoma Myeloma 9(Suppl 1):Abstract #352 Dhawan R, Meunier J, Regnault R et al (2009) Impact of complete response on health-related quality of life in newly diagnosed multiple myeloma patients: results from the VISTA trial. Clin Lymphoma Myeloma 9(Suppl 1):Abstract #352
15.
Zurück zum Zitat Palumbo A, Bringhen S, Rossi D et al (2009) Bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients: a prospective, randomized phase III study. Haematologica 94(Suppl 2):Abstract #472 Palumbo A, Bringhen S, Rossi D et al (2009) Bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients: a prospective, randomized phase III study. Haematologica 94(Suppl 2):Abstract #472
16.
Zurück zum Zitat Mateos MV, Oriol A, Martinez J et al (2009) Bortezomib (Velcade)/melphalan/prednisone (VMP) versus Velcade/thalidomide/prednisonse (VTP) in elderly untreated multiple myeloma (MM) patients. Haematologica 94(Suppl 2):Abstract #471 Mateos MV, Oriol A, Martinez J et al (2009) Bortezomib (Velcade)/melphalan/prednisone (VMP) versus Velcade/thalidomide/prednisonse (VTP) in elderly untreated multiple myeloma (MM) patients. Haematologica 94(Suppl 2):Abstract #471
17.
Zurück zum Zitat Rajkumar SV, Jacobus S, Callander NS et al (2009) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol [Epub ahead of print] Rajkumar SV, Jacobus S, Callander NS et al (2009) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol [Epub ahead of print]
18.
Zurück zum Zitat Palumbo A, Falco P, Falcone A et al (2009) Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: Kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin Lymphoma Myeloma 9:145–150CrossRefPubMed Palumbo A, Falco P, Falcone A et al (2009) Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: Kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin Lymphoma Myeloma 9:145–150CrossRefPubMed
19.
Zurück zum Zitat Palumbo A, Dimopoulos MA, Delforge M et al (2009) A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Presented at: 2009 meeting of the American Society of Hematology, New Orleans Abstract #613, Blood 114:253 Palumbo A, Dimopoulos MA, Delforge M et al (2009) A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Presented at: 2009 meeting of the American Society of Hematology, New Orleans Abstract #613, Blood 114:253
20.
Zurück zum Zitat Richardson PG, Lonial S, Jakubowiak A et al (2008) Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: Encouraging efficacy in high risk groups with updated results of a phase I/II study. Presented at: 2008 meeting of the American Society of Hematology in San Francisco. Blood 112:Abstract #92 Richardson PG, Lonial S, Jakubowiak A et al (2008) Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: Encouraging efficacy in high risk groups with updated results of a phase I/II study. Presented at: 2008 meeting of the American Society of Hematology in San Francisco. Blood 112:Abstract #92
21.
Zurück zum Zitat Kumar S, Flinn IW, Noga SJ et al (2008) Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: Initial results from the phase I/II multi-center EVOLUTION study. Presented at: 2008 meeting of the American Society of Hematology in San Francisco. Blood 112:Abstract #93CrossRef Kumar S, Flinn IW, Noga SJ et al (2008) Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: Initial results from the phase I/II multi-center EVOLUTION study. Presented at: 2008 meeting of the American Society of Hematology in San Francisco. Blood 112:Abstract #93CrossRef
22.
Zurück zum Zitat Kumar S, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520CrossRefPubMed Kumar S, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520CrossRefPubMed
23.
Zurück zum Zitat Morgan GJ, Jackson GH, Davies FE et al (2008) Maintenance thalidomide may improve progression free but not overall survival; Results from the myeloma IX maintenance randomisation. Presented at: 2008 meeting of the American Society of Hematology in San Francisco. Blood 112:Abstract #656 Morgan GJ, Jackson GH, Davies FE et al (2008) Maintenance thalidomide may improve progression free but not overall survival; Results from the myeloma IX maintenance randomisation. Presented at: 2008 meeting of the American Society of Hematology in San Francisco. Blood 112:Abstract #656
24.
Zurück zum Zitat Ludwig H, Adam Z, Tóthová E et al (2009) Thalidomide-interferon vs. Interferon maintenance therapy after thal-dex vs. MP induction therapy in elderly patients with multiple myeloma. Presented at: 2009 meeting of the American Society of Hematology, New Orleans. Abstract #2891, Blood 114:1129 Ludwig H, Adam Z, Tóthová E et al (2009) Thalidomide-interferon vs. Interferon maintenance therapy after thal-dex vs. MP induction therapy in elderly patients with multiple myeloma. Presented at: 2009 meeting of the American Society of Hematology, New Orleans. Abstract #2891, Blood 114:1129
25.
Zurück zum Zitat Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825–831CrossRefPubMed Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825–831CrossRefPubMed
Metadaten
Titel
Konventionelle Behandlung von Patienten mit multiplem Myelom
verfasst von
Prof. Dr. H. Ludwig
N. Zojer
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 3/2010
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-010-1796-8

Weitere Artikel der Ausgabe 3/2010

Der Onkologe 3/2010 Zur Ausgabe

CME Weiterbildung · Zertifizierte Fortbildung

Chirurgie der Schilddrüsenkarzinome

Neu im Fachgebiet Onkologie

Muskeln trainieren gegen Nervenschäden durch Chemotherapie

17.07.2024 Nebenwirkungen der Krebstherapie Nachrichten

Chemotherapien können die Nerven schädigen und damit die Lebensqualität von Betroffenen zusätzlich einschränken. Wer aber auf die richtige Art trainiert, kann das absolute Risiko für Neuropathien um bis zu 40% senken.

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen. Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom etwa hatten das beste Outcome, wenn die PD-1-Inhibitor-Infusionen in den Wintermonaten starteten.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.